TY  - JOUR
AU  - Martínez Cuadrón, David
AU  - Gil, Cristina
AU  - Serrano, Josefina
AU  - Rodríguez, Gabriela
AU  - Pérez Oteyza, Jaime
AU  - García Boyero, Raimundo
AU  - Jiménez Bravo, Santiago
AU  - Vives, Susana
AU  - Vidriales, María Belén
AU  - Lavilla, Esperanza
AU  - Pérez Simón, José A.
AU  - Tormo, Mar
AU  - Colorado, Mercedes
AU  - Bergua, Juan
AU  - López, Juan A.
AU  - Herrera, Pilar
AU  - Hernández Campo, Pilar
AU  - Gorrochategui, Julián
AU  - Primo, Daniel
AU  - Rojas, Jose Luis
AU  - Villoria, Jesús
AU  - Moscardó, Federico
AU  - Troconiz, Iñaki
AU  - Linares Gómez, María
AU  - Martínez López, Joaquín
AU  - Ballesteros, Joan
AU  - Sanz, Miguel
AU  - Montesinos, Pau
PY  - 2019
DO  - 10.1016/j.leukres.2018.11.006
SN  - 0145-2126
UR  - https://hdl.handle.net/20.500.14352/101712
AB  - Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML) patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi rate after idarubicin (IDA) and...
LA  - eng
KW  - Acute myeloid leukemia
KW  - Pharmacological profile
KW  - Complete remission
KW  - Clinical correlation
KW  - Ex vivo assay
TI  - A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
TY  - journal article
ER  -